Atrium Therapeutics Announces $15M Milestone Payment From Bristol Myers Squibb On Delivery Of Second Lead Compound In Undisclosed Cardiology Indication

Loading news article.

Atrium Therapeutics Announces $15M Milestone Payment From Bristol Myers Squibb On Delivery Of Second Lead Compound In Undisclosed Cardiology Indication | WAPE

Atrium Therapeutics Announces $15M Milestone Payment From Bristol Myers Squibb On Delivery Of Second Lead Compound In Undisclosed Cardiology Indication

Article summary

Related companies

Comments —